Please assess the completion status of the following clinical trial:

Trial Title: Feasibility of Short-Term PrEP Uptake for MSM With Episodic High-Risk for HIV

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Self-identify as MSM: (1) born male who (2) has sex with men~* Age: 18 or older~* Sexual Risk: has had condomless anal sex with 2 or more men or any transactional sex with a man within the past 12-months.~* Vacation: identified an upcoming period of episodic risk away (i.e. vacation) from their home city that will last at least 7 but not more than 14 days during which they anticipate having at least one high-risk sexual event.~* Able and willing to provide informed consent~Exclusion Criteria:~* HIV positive~* Glomerular filtration rate \< 60 mL/min (calculated using the Cockcroft-Gault formula)~* Hepatitis B surface antigen positive~* Symptoms suggestive of acute HIV seroconversion at screening or enrollment~* Have used PrEP or PEP within the previous 3 months~* Currently enrolled in another study involving medications, investigational drug, or medical device~* Has other conditions (based on opinion of investigator or designee) that would preclude informed consent, make the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with study procedures

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Intervention (Type: EXPERIMENTAL): Given emtricitabine/tenofovir for 2-3 weeks. Brief CBT-based counseling to promote PrEP adherence

Based on this trial design, predict the completion outcome and termination type (if applicable).